Hepatitis C treatment and long-term outcome of patients with hepatocellular carcinoma after resection.
direct-acting antiviral therapy
hepatectomy
hepatitis C virus
hepatocellular carcinoma
interferon
outcome
survival
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
28
05
2023
received:
23
01
2023
accepted:
15
06
2023
medline:
18
9
2023
pubmed:
5
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
This study aimed to investigate the survival outcomes of antiviral agents (direct-acting antivirals [DAAs] or interferon [IFN]) in patients with hepatitis C virus who underwent liver resection for primary hepatocellular carcinoma. This retrospective single-center study included 247 patients, between 2013 and 2020, being treated with DAAs (n = 93), IFN (n = 73), or no treatment (n = 81). Overall survival (OS), recurrence-free survival (RFS), and risk factors were analyzed. After a median follow-up time of 50.4 months, the rates of 5-year OS and RFS in the IFN, DAA, and no treatment groups were 91.5% and 55.4%, 87.2% and 39.8%, and 60.9% and 26.7%, respectively. One hundred and twenty-eight (51.6%) patients developed recurrence; recurrence was mostly (86.7%) intrahepatic, and 58 (23.4%) developed early recurrence, most of which received no antiviral treatment. The OS and RFS were similar between patients who received antiviral treatment before (50.0%) and after surgery, but longer survival was observed in patients achieving sustained virologic response. In multivariate analysis, antiviral treatment was protective for OS (hazard ratio [HR] 0.475, 95% confidence interval [CI]: 0.242-0.933) with significance but not RFS, in contrast to microvascular invasion (OS HR 3.389, 95% CI: 1.637-7.017; RFS HR 2.594, 95% CI: 1.520-4.008). In competing risk analysis, DAAs (subdistribution HR 0.086, 95% CI: 0.007-0.991) were protective against hepatic decompensation events but not recurrence events. In patients with hepatitis C virus, antiviral treatment suggested OS benefit for primary hepatocellular carcinoma after resection, and DAAs might be protective against hepatic decompensation. Following adjustment for oncological factors, IFN and DAA treatment was not significantly advantageous relative to the other.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
This study aimed to investigate the survival outcomes of antiviral agents (direct-acting antivirals [DAAs] or interferon [IFN]) in patients with hepatitis C virus who underwent liver resection for primary hepatocellular carcinoma.
METHODS
METHODS
This retrospective single-center study included 247 patients, between 2013 and 2020, being treated with DAAs (n = 93), IFN (n = 73), or no treatment (n = 81). Overall survival (OS), recurrence-free survival (RFS), and risk factors were analyzed.
RESULTS
RESULTS
After a median follow-up time of 50.4 months, the rates of 5-year OS and RFS in the IFN, DAA, and no treatment groups were 91.5% and 55.4%, 87.2% and 39.8%, and 60.9% and 26.7%, respectively. One hundred and twenty-eight (51.6%) patients developed recurrence; recurrence was mostly (86.7%) intrahepatic, and 58 (23.4%) developed early recurrence, most of which received no antiviral treatment. The OS and RFS were similar between patients who received antiviral treatment before (50.0%) and after surgery, but longer survival was observed in patients achieving sustained virologic response. In multivariate analysis, antiviral treatment was protective for OS (hazard ratio [HR] 0.475, 95% confidence interval [CI]: 0.242-0.933) with significance but not RFS, in contrast to microvascular invasion (OS HR 3.389, 95% CI: 1.637-7.017; RFS HR 2.594, 95% CI: 1.520-4.008). In competing risk analysis, DAAs (subdistribution HR 0.086, 95% CI: 0.007-0.991) were protective against hepatic decompensation events but not recurrence events.
CONCLUSION
CONCLUSIONS
In patients with hepatitis C virus, antiviral treatment suggested OS benefit for primary hepatocellular carcinoma after resection, and DAAs might be protective against hepatic decompensation. Following adjustment for oncological factors, IFN and DAA treatment was not significantly advantageous relative to the other.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1618-1628Informations de copyright
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71: 209-249.
Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol.; 2017: 1683-1691.
McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30: 1969-1983.
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat. Rev. Dis. Primers. 2017; 3: 17006.
Yu ML, Chen PJ, Dai CY et al. 2020 Taiwan Consensus Statement on the management of hepatitis C: part (I) general population. J. Formos. Med. Assoc. 2020; 119: 1019-1040.
European Association for the Study of the Liver, Clinical Practice Guidelines Panel, EASL Governing Board representative. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 2020; 73: 1170-1218.
Nahon P, Bourcier V, Layese R et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152: 142-156.e2.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 2013; 158: 329-337.
Wu KC, Lee IC, Chi CT et al. Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. Am. J. Cancer Res. 2021; 11: 5526-5542.
Kao JH. Hepatitis C virus infection in Taiwan: past, present, and future. J. Formos. Med. Assoc. 2016; 115: 65-66.
Wu GH, Pwu RF, Chen SC. Achieving hepatitis C elimination in Taiwan-overcoming barriers by setting feasible strategies. J. Formos. Med. Assoc. 2018; 117: 1044-1045.
Waziry R, Hajarizadeh B, Grebely J et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J. Hepatol. 2017; 67: 1204-1212.
Cabibbo G, Celsa C, Calvaruso V et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J. Hepatol. 2019; 71: 265-273.
Fukumoto T, Minami T, Moriyama M et al. Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. Hepatol Commun. 2022; 6: 2496-2512.
Ochi H, Hiraoka A, Hirooka M et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J. Gastroenterol. 2021; 56: 90-100.
Nishibatake Kinoshita M, Minami T, Tateishi R et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J. Hepatol. 2019; 70: 78-86.
Singal AG, Rich NE, Mehta N et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019; 156: 1683-1692.e1.
Reig M, Marino Z, Perello C et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 2016; 65: 719-726.
Lui FH, Moosvi Z, Patel A, Hussain S, Duong A, Duong J, Nguyen DL. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann. Gastroenterol. 2020; 33: 293-298.
Omata M, Kanda T, Wei L et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016; 10: 702-726.
Liu CH, Liang CC, Lin JW et al. Pegylated interferon α-2a versus standard interferon α-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530.
Hong CM, Liu CH, Su TH et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data. J. Microbiol. Immunol. Infect. 2020; 53: 569-577.
Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann. Surg. Oncol. 2012; 19: 826-833.
Cheng HY, Ho CM, Hsiao CY, Ho MC, Wu YM, Lee PH, Hu RH. Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. HPB (Oxford) 2023; 25: 218-228.
Ho CM, Lee CH, Lee MC et al. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis. Front. Oncol. 2020; 10: 616094.
Hong YM, Cho M, Yoon KT, Chu CW, Yang KH, Park YM, Rhu JH. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma. Tumour Biol. 2017; 39: 1010428317720863.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 2015; 33: 550-558.
D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J. Hepatol. 2022; 76: 202-207.
Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1437.e1-1437.e9.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999; 94: 496-509.
Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020; 8: e000262.
Romano A, Angeli P, Piovesan S et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J. Hepatol. 2018; 69: 345-352.
Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010; 16: 748-759.
Cholankeril G, Joseph-Talreja M, Perumpail BJ, Liu A, Yoo ER, Ahmed A, Goel A. Timing of hepatitis C virus treatment in liver transplant candidates in the era of direct-acting antiviral agents. J. Clin. Transl. Hepatol. 2017; 5: 363-367.
van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
Martini S, Sacco M, Strona S et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int. 2017; 37: 62-70.
Rockey DC, Friedman SL. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. Gastroenterology 2021; 160: 1502-1520.e1.
Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.
Mohanty A, Salameh S, Butt AA. Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection. Curr. HIV/AIDS Rep. 2019; 16: 389-394.
Mucke MM, Mucke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int. 2018; 38: 14-20.
Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 2019; 156: 446-460.e2.
van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J. Hepatol. 2016; 65: S95-S108.
Calvaruso V, Craxi A. Hepatic benefits of HCV cure. J. Hepatol. 2020; 73: 1548-1556.
Curry MP. Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established. J. Hepatol. 2016; 64: 1206-1207.
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg. 2015; 261: 947-955.
Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann. Surg. Oncol. 2019; 26: 1474-1493.
Frazzoni L, Sikandar U, Metelli F et al. Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis. J. Clin. Med. 2021; 10: 1694.
Guarino M, Di Costanzo GG, Bruzzese D et al. Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. Liver Cancer Int. 2020; 1: 12-24.
Takata M, Yamanaka N, Tanaka T et al. What patients can survive disease free after complete resection for hepatocellular carcinoma?: a multivariate analysis. Jpn. J. Clin. Oncol. 2000; 30: 75-81.
Tanaka S, Tamori A, Takemura S, Hamano G, Ito T, Kawada N, Kubo S. Surgical outcomes in hepatitis C virus-related hepatocellular carcinoma: special reference to sustained virological responses to interferon therapy. Am. Surg. 2017; 83: 1246-1255.
Koda M, Tanaka S, Takemura S et al. Long-term prognostic factors after hepatic resection for hepatitis C virus-related hepatocellular carcinoma, with a special reference to viral status. Liver Cancer. 2018; 7: 261-276.
Tanaka S, Shinkawa H, Tamori A et al. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals. J. Surg. Oncol. 2020; 122: 1543-1552.
Chen YS, Huang KH, Wang PM et al. The impact of direct-acting antiviral therapy on the risk of recurrence after curative resection in patients with hepatitis-C-virus-related early stage hepatocellular carcinoma. Medicina (Kaunas) 2022; 58: 259.